[go: up one dir, main page]

BRPI1006534A2 - sal do composto 1, processo para preparar um sal do composto 1, e processo para preparar um sal misto do composto 1 - Google Patents

sal do composto 1, processo para preparar um sal do composto 1, e processo para preparar um sal misto do composto 1

Info

Publication number
BRPI1006534A2
BRPI1006534A2 BRPI1006534A BRPI1006534A BRPI1006534A2 BR PI1006534 A2 BRPI1006534 A2 BR PI1006534A2 BR PI1006534 A BRPI1006534 A BR PI1006534A BR PI1006534 A BRPI1006534 A BR PI1006534A BR PI1006534 A2 BRPI1006534 A2 BR PI1006534A2
Authority
BR
Brazil
Prior art keywords
compound
salt
preparing
mixed
mixed salt
Prior art date
Application number
BRPI1006534A
Other languages
English (en)
Inventor
Gary Bartley
John F Lang
Thomas Cleary
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BRPI1006534A2 publication Critical patent/BRPI1006534A2/pt
Publication of BRPI1006534B1 publication Critical patent/BRPI1006534B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1006534-2A 2009-03-24 2010-03-24 Sal do composto 1, processo para preparar um sal do composto 1, e processo para preparar um sal misto do composto 1 BRPI1006534B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16280509P 2009-03-24 2009-03-24
US61/162,805 2009-03-24
PCT/US2010/028490 WO2010111381A2 (en) 2009-03-24 2010-03-24 Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Publications (2)

Publication Number Publication Date
BRPI1006534A2 true BRPI1006534A2 (pt) 2016-08-02
BRPI1006534B1 BRPI1006534B1 (pt) 2021-05-25

Family

ID=42781851

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006534-2A BRPI1006534B1 (pt) 2009-03-24 2010-03-24 Sal do composto 1, processo para preparar um sal do composto 1, e processo para preparar um sal misto do composto 1

Country Status (17)

Country Link
US (1) US8501753B2 (pt)
EP (1) EP2411394B1 (pt)
JP (1) JP5766687B2 (pt)
KR (1) KR101763672B1 (pt)
CN (1) CN102448963B (pt)
AU (1) AU2010230008B2 (pt)
BR (1) BRPI1006534B1 (pt)
CA (1) CA2755950C (pt)
EA (1) EA020931B1 (pt)
ES (1) ES2519568T3 (pt)
IL (1) IL215298A (pt)
MX (1) MX2011009928A (pt)
NZ (1) NZ595590A (pt)
PL (1) PL2411394T3 (pt)
RU (1) RU2489435C2 (pt)
SG (1) SG174517A1 (pt)
WO (1) WO2010111381A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
EA025252B1 (ru) 2010-07-22 2016-12-30 Гайлид Сайэнсиз, Инк. Способы и соединения для лечения вирусных инфекций paramyxoviridae
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
KR102911165B1 (ko) 2020-06-24 2026-01-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
KR102580079B1 (ko) * 2020-10-29 2023-09-19 한양대학교 산학협력단 기생 인덕턴스 감소를 위한 적층형 회로 구조체
GB202110403D0 (en) * 2021-07-20 2021-09-01 Laevoroc Immunology Ulodesine Salt
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870732A (en) 1973-08-21 1975-03-11 Velsicol Chemical Corp Mixed salts of aluminum
US5386031A (en) * 1993-12-15 1995-01-31 Warner-Lambert Company Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
JP2002500658A (ja) * 1997-05-29 2002-01-08 ノバルティス アクチエンゲゼルシャフト 2−アミノ−7−(1−置換−2−ヒドロキシエチル)−3,5−ジヒドロピロロ[3,2−d]ピリミジン−4−オン
DE60336734D1 (de) * 2002-08-21 2011-05-26 Ind Res Ltd Sidasen
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides

Also Published As

Publication number Publication date
PL2411394T3 (pl) 2015-01-30
RU2489435C2 (ru) 2013-08-10
CA2755950C (en) 2017-04-25
KR101763672B1 (ko) 2017-08-01
IL215298A0 (en) 2011-12-29
KR20120005466A (ko) 2012-01-16
CA2755950A1 (en) 2010-09-30
MX2011009928A (es) 2012-03-16
CN102448963B (zh) 2015-06-17
US8501753B2 (en) 2013-08-06
AU2010230008A1 (en) 2011-10-06
EA201190205A1 (ru) 2012-06-29
US20120165526A1 (en) 2012-06-28
RU2011141212A (ru) 2013-04-27
WO2010111381A3 (en) 2011-03-31
JP2012521992A (ja) 2012-09-20
ES2519568T3 (es) 2014-11-07
EP2411394A2 (en) 2012-02-01
AU2010230008B2 (en) 2015-06-04
BRPI1006534B1 (pt) 2021-05-25
EP2411394A4 (en) 2012-08-15
HK1170486A1 (en) 2013-03-01
EA020931B1 (ru) 2015-02-27
EP2411394B1 (en) 2014-08-06
JP5766687B2 (ja) 2015-08-19
IL215298A (en) 2017-04-30
WO2010111381A2 (en) 2010-09-30
CN102448963A (zh) 2012-05-09
SG174517A1 (en) 2011-10-28
NZ595590A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
BRPI1006534A2 (pt) sal do composto 1, processo para preparar um sal do composto 1, e processo para preparar um sal misto do composto 1
BRPI0918038A2 (pt) Processos para preparar um composto e um sal, e, composto
BRPI0910910A2 (pt) processo para preparar um composto
BRPI0910911A2 (pt) processo para preparar um composto
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0919018A2 (pt) sal farmaceuticamente aceitável, uso de sal, e, processo para a preparação de sal
BRPI0911041A2 (pt) processo para a preparação de sal de polímero de amina
BRPI1012018A2 (pt) processo para preparar um composto
BRPI0923007A2 (pt) Sal de piperazina e um processo para preparação do mesmo
BRPI0820851A2 (pt) Processo para preparar microcápsulas
BRPI1010933A2 (pt) processo para a preparação de um pó, e, composto
BR112013011574A2 (pt) composição de fertilizante de liberação controlada, e, processo para produzir um fertilizante de liberação controlada
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI0922836A2 (pt) processo para a preparação de um sal de succinato monovalente
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BR112013010075A2 (pt) compostos intermediários e processo para a preparação de fingolimod
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BR112014003111A2 (pt) “processo para preparar um composto de 1h-pirazol-5- carbonilcloreto n-substituído e processo para preparar um composto de sulfimina”
BR112012029226A2 (pt) processo para a preparação de um composto quiral, composto quiral cristalino, sal de hcl do composto quiral cristalino, composto quiral e uso do composto
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
BRPI0914674A2 (pt) processo para preparação de um pó
BR112013007040A2 (pt) "método para preparar um composto e composto"
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0921420A2 (pt) processo para preparar compostos
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 487/04 , C07D 403/04

Ipc: C07D 487/04 (2006.01), C07D 403/04 (2006.01), A61K

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF